The company's proprietary technology platform enables the discovery and development of superior antibody product candidates that are able to impact previously inaccessible disease mechanisms. Apexigen pioneers a movement into therapeutics based on rabbit-derived humanized monoclonal antibodies, which have the ability to generate a much greater diversity of unique high-quality antibodies with high affinity, high specificity, and which bind unique antigen epitopes. The company's focus is on developing a new generation of antibody therapeutics for the treatment of cancer, with an emphasis on new immuno-oncology products designed to harness the patient’s immune system to combat and eradicate cancer. Its lead immuno-oncology drug candidate, sotigalimab, is a potent immune-activating antibody against CD40 currently in Phase 2 clinical development.